|
 i2020 Accelerator Invests in Developing Novel Highly-Specific Approaches to Treatment of Neurodegenerative Diseases Based on Previously Unrecognized Protein-Protein Interactions
Viriom Wins Grant Award To Establish Affiliate In Mainland China
Viriom announces NIH/NIAID and Division of AIDS Collaboration with the Long-Acting/Extended Release Antiviral Resource Program
Snap Bio and i2020 Accelerator (Torrey Pines Investment) Reach Lead Compounds Milestone for Pediatric Oncology and Advanced Liver Cancer Programs
Viriom Signed Licensing Agreement for Indonesia with P.T. Lloyd Pharma
Viriom Files for Market Authorization in China
Viriom Announces New CEO Appointment
Viriom Initiates Phase 1 Clinical Trial of Once Monthly Injectable HIV Treatment
Torrey Pines Investment's i2020 Accelerator to Advance Snap Bio's Selective Kinase Inhibitor Platform for Treatment of Endodermal Cancers and Autoimmune Diseases
Leap Therapeutics Reports Third Quarter 2018 Business Update and Financial Results
Torrey Pines Invests in 19Labs' Innovative Telehealth 2.0 Point of Care Solutions
Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting
Viriom to Present Pre-Clinical Studies with Elsulfavirine/VM1500A Long-Acting Parenteral and Oral Formulations at the International Conference on HIV/AIDS, STDs & STIs 2018
i2020 to Accelerate Stelvio Therapeutics First-in-Class Epigenetic Platform for Glioblastoma
Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting
Torrey Pines Launches i2020 Accelerator for Early Therapeutics
Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial
Torrey Pines Investment announced today the launch and initial funding of its i2020 Accelerator initiative.
ChemDiv, DZNE and Torrey Pines Investment Launch Inflammasome Discovery Program of Translational Collaboration on Neurodegeneration
ChemDiv and Abbott expand collaboration to develop branded generic pharmaceuticals for high growth emerging markets
ChemDiv, Context Therapeutics and Torrey Pines Investment Announce CNS Co-Development Agreement
Tensha Therapeutics To Be Acquired By Roche
ChemDiv Announces Achievement of a Development Milestone in a Drug Discovery Collaboration With Janssen
BioIntegrator Announced Launch of Neskler® -- a Generic of Novartis MS Blockbuster Gilenya® in Emerging Markets
J.P. Morgan 34th Annual Healthcare Conference
Viriom presented the results of the safety and antiviral effect of its novel drug Elpida® at the EACS-2015 conference in Barcelona
Avineuro LLC advances its highly selective 5-HT6R antagonist program in Alzheimer Disease
TeaRx launches an innovative anticoagulant Tearexaban
Ron Demuth Interviewed for Nature Drug Discovery News Article
Avelas Biosciences Completes 7.4M Funding
T23 Announces Global License of SCRIPPS’ CD22 Siglec Oncoimmunological Platform for B-cell Tumors
Viriom is Expanding its Portfolio of Novel Antiviral Drugs
ChemRar HighTech Center is featured in Pharmaceutical Executive article “Russia’s Bet on Biopharma”
|
